News & Updates

Time to recovery from COVID-19 pneumonia does not appear to differ following treatment with abatacept, cenicriviroc, or infliximab among hospitalized patients, according to a study.

Longyizhengqi (LYZQ) granule, a traditional Chinese medicine (TCM), might be a promising drug for the treatment of mild COVID-19 caused by the Omicron variant, a prospective study from China suggests.

A prediction model on disease recurrence for low-risk, resected stage I lung adenocarcinoma can classify postoperative patients with available clinical information and may even aid in personalizing a follow-up strategy and future adjuvant therapy, reports a study.

Providing palliative care (PC) for patients with interstitial lung disease (ILD) appears more challenging than for those with lung cancer (LC), according to a study. Pulmonary specialists have also cited some ILD-specific barriers in PC.

Treatment with fixed-dose asthma inhaler combination of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) helps improve lung function and reduce exacerbations as compared with MF/IND and fluticasone/salmeterol (FLU/SAL), regardless of baseline eosinophil levels, according to a post hoc analysis of the IRIDIUM study.

A technology-enabled virtual ward may be a feasible alternative to hospitalization for high-risk COVID-19 patients such as the elderly and the immunocompromised, a retrospective cohort study from Singapore suggests.

In the treatment of patients with mild-to-moderate COVID-19, adding fluvoxamine to favipiravir does not appear to prevent disease progression or improve certain outcomes, according to the results of an open-label study.